"კ. ერისთავის სახელობის ექსპერიმენტული და კლინიკური ქირურგიის ეროვნული ცენტრი საქართველოში სამედიცინო დაწესებულებათა შორის ერთ-ერთი უძველესია. მისი ისტორია იწყება 1946 წლიდან და სამედიცინო საქმიანობათა ტრადიცია დღემდე უწყვეტად გრძელდება. თანამედროვე მედიცინის მიღწევებზე საუბრისას თვალწინ წარმოგვიდგება უახლესი აპარატურა, თანამედროვე კლინიკები, უნიკალური ოპერაციები, რასაც თან ახლავს პროფესიონალთა დიდი ძალისხმევის ფონზე მიღებული შედეგებით მიღწეული წარმატების უდიდესი ემოცია. თამამად შეიძლება ითქვას, რომ ამ სტანდარტებს სრულად აკმაყოფილებს ჩვენი კლინიკა. ესაა პროგრესულად მოაზროვნე მენეჯმენტის, უახლესი სამედიცინო აპარატურის და, რაც მთავარია, უმაღლესი კვალიფიკაციის პროფესიონალ ექიმთა ერთობლიობა."

During the past decade, JSC K. Eristavi National Center of Experimental and Clinical Surgery conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" #1 sponsor was "Catalyst Biosciences" with 2 trials, followed by "CTI BioPharma" with 1 trials sponsored, "Cubist Pharmaceuticals LLC" with 1 trials sponsored, "Geron Corporation" with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" #1 collaborator was "PSI CRO" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" are "Hemophilia A With Inhibitor" (2 trials), "Hemophilia B With Inhibitor" (2 trials), "Arthritis, Psoriatic" (1 trials), "Complicated Intra-abdominal Infection" (1 trials) and "Hemophilia B" (1 trials). Many other conditions were trialed in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" in a lesser frequency.

Most popular intervention types in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" are "Drug" (7 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "APVO101" (1 trials), "Best Available Therapy (BAT)" (1 trials), "Bupivacaine HCl" (1 trials), "CXA-101/ tazobactam and metronidazole" (1 trials) and "Coagulation Factor VIIa variant" (1 trials). Other intervention names were less common.

The vast majority of trials in "JSC K. Eristavi National Center of Experimental and Clinical Surgery" are 8 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "JSC K. Eristavi National Center of Experimental and Clinical Surgery". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in JSC K. Eristavi National Center of Experimental and Clinical Surgery, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in JSC K. Eristavi National Center of Experimental and Clinical Surgery, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

JSC K. Eristavi National Center of Experimental and Clinical Surgery has several departments that took part in Clinical trials: "National Center of Therapy" - 3 trials